Ontology type: schema:ScholarlyArticle
2013-12
AUTHORSS. F. Dent, K. A. Gelmon, K. N. Chi, D. J. Jonker, N. Wainman, C. A. Capier, E. X. Chen, J. F. Lyons, L. Seymour
ABSTRACTPURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmacodynamic properties of AT9283. PATIENTS AND METHODS: Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. A 3 + 3 dose escalation design was used with a starting dose of 1.5 mg/m(2)/day. Pharmacokinetic samples were collected from all patients on cycle one, and pharmacodynamic samples were collected from 4 patients at the recommended phase II dose (RP2D). RESULTS: 35 patients were evaluable for toxicity and 32 were evaluable for response. AT9283 was well tolerated, with main toxicities being reversible dose-related fatigue, gastrointestinal disturbance, anemia, lymphocytopenia and neutropenia. The dose limiting toxicities were febrile neutropenia (two patients) and neutropenia with grade 3 infection (1 patient) at 47 mg/m(2)/day (established as the maximum tolerated dose). The RP2D was 40 mg/m(2)/day. Pharmacokinetic analyses showed AT9283 appeared to follow linear kinetics, with a mean elimination half-life of 8.2 h. Pharmacodynamic analyses showed no consistent or significant changes, but trends suggested evidence of AT9283 inhibition and anti-proliferative activity. One patient had partial response and four patients experienced RECIST stable disease (median 2.6 months). CONCLUSION: In this study, AT9283 was well tolerated. The RP2D is 40 mg/m(2)/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers. More... »
PAGES1522-1529
http://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9
DOIhttp://dx.doi.org/10.1007/s10637-013-0018-9
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1030261706
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/24072436
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Benzimidazoles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Administration Schedule",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Histones",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infusions, Intravenous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ki-67 Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Proliferating Cell Nuclear Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein Kinase Inhibitors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Skin",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tumor Suppressor Protein p53",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Urea",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"name": [
"Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Rd, K1H 8L6, Ottawa, ON, Canada"
],
"type": "Organization"
},
"familyName": "Dent",
"givenName": "S. F.",
"id": "sg:person.01005512156.68",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005512156.68"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"Division of Medical Oncology, BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Gelmon",
"givenName": "K. A.",
"id": "sg:person.01173252503.80",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173252503.80"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"Division of Medical Oncology, BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Chi",
"givenName": "K. N.",
"id": "sg:person.01142252161.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142252161.65"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, 501 Smyth Rd, K1H 8L6, Ottawa, ON, Canada"
],
"type": "Organization"
},
"familyName": "Jonker",
"givenName": "D. J.",
"id": "sg:person.0602472015.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602472015.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University",
"id": "https://www.grid.ac/institutes/grid.410356.5",
"name": [
"NCIC Clinical Trials Group, Cancer Research Institute, Kingston, ON, Canada"
],
"type": "Organization"
},
"familyName": "Wainman",
"givenName": "N.",
"id": "sg:person.0725434730.09",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725434730.09"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "BC Cancer Agency",
"id": "https://www.grid.ac/institutes/grid.248762.d",
"name": [
"BC Cancer Agency - Vancouver Cancer Centre, Vancouver, BC, Canada"
],
"type": "Organization"
},
"familyName": "Capier",
"givenName": "C. A.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Princess Margaret Cancer Centre",
"id": "https://www.grid.ac/institutes/grid.415224.4",
"name": [
"University Health Network-Princess Margaret Hospital, Oncology, Toronto, ON, Canada"
],
"type": "Organization"
},
"familyName": "Chen",
"givenName": "E. X.",
"id": "sg:person.0754450325.91",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754450325.91"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Astex Pharmaceuticals, Cambridge, UK"
],
"type": "Organization"
},
"familyName": "Lyons",
"givenName": "J. F.",
"id": "sg:person.01133244421.43",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133244421.43"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Queen's University",
"id": "https://www.grid.ac/institutes/grid.410356.5",
"name": [
"NCIC Clinical Trials Group, Cancer Research Institute, Kingston, ON, Canada"
],
"type": "Organization"
},
"familyName": "Seymour",
"givenName": "L.",
"id": "sg:person.01327242410.25",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327242410.25"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00280-010-1377-y",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003176121",
"https://doi.org/10.1007/s00280-010-1377-y"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0962-8924(00)01880-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1005800453"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jnci/91.13.1160",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006611610"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2010.15",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007310794",
"https://doi.org/10.1038/leu.2010.15"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/path.1711690415",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009072534"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jnci/94.17.1320",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1009989679"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-07-0431",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011939272"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1078-0432.ccr-07-5268",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1016270721"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1158/1535-7163.mct-10-0299",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1020215440"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/emboj/17.11.3052",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022175488"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ijc.1200",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1031753113"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/jnci/92.3.205",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032301848"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ijc.26324",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035093358"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1182/blood-2006-07-037671",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035758193"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.3324/haematol.12148",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1036865215"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1054/bjoc.2000.1684",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037558742",
"https://doi.org/10.1054/bjoc.2000.1684"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1093/annonc/mdr451",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041877696"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrm1245",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049953107",
"https://doi.org/10.1038/nrm1245"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrm1245",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1049953107",
"https://doi.org/10.1038/nrm1245"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/35048096",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051541099",
"https://doi.org/10.1038/35048096"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/35048096",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051541099",
"https://doi.org/10.1038/35048096"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/jm800984v",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055955939"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/jm800984v",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055955939"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.4161/cc.8.12.8741",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1072300058"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1075250639",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1075266210",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1077018133",
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1200/jco.2008.26.15_suppl.2519",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1079371368"
],
"type": "CreativeWork"
}
],
"datePublished": "2013-12",
"datePublishedReg": "2013-12-01",
"description": "PURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmacodynamic properties of AT9283.\nPATIENTS AND METHODS: Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. A 3 + 3 dose escalation design was used with a starting dose of 1.5 mg/m(2)/day. Pharmacokinetic samples were collected from all patients on cycle one, and pharmacodynamic samples were collected from 4 patients at the recommended phase II dose (RP2D).\nRESULTS: 35 patients were evaluable for toxicity and 32 were evaluable for response. AT9283 was well tolerated, with main toxicities being reversible dose-related fatigue, gastrointestinal disturbance, anemia, lymphocytopenia and neutropenia. The dose limiting toxicities were febrile neutropenia (two patients) and neutropenia with grade 3 infection (1 patient) at 47 mg/m(2)/day (established as the maximum tolerated dose). The RP2D was 40 mg/m(2)/day. Pharmacokinetic analyses showed AT9283 appeared to follow linear kinetics, with a mean elimination half-life of 8.2 h. Pharmacodynamic analyses showed no consistent or significant changes, but trends suggested evidence of AT9283 inhibition and anti-proliferative activity. One patient had partial response and four patients experienced RECIST stable disease (median 2.6 months).\nCONCLUSION: In this study, AT9283 was well tolerated. The RP2D is 40 mg/m(2)/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers.",
"genre": "research_article",
"id": "sg:pub.10.1007/s10637-013-0018-9",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1094201",
"issn": [
"0167-6997",
"1573-0646"
],
"name": "Investigational New Drugs",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "31"
}
],
"name": "NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies",
"pagination": "1522-1529",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"9029856cbb059630e633c78f2e4fc60afab3851146d17aa78dc1cb765afd2c47"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"24072436"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"8309330"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10637-013-0018-9"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1030261706"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10637-013-0018-9",
"https://app.dimensions.ai/details/publication/pub.1030261706"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T18:20",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000513.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1007%2Fs10637-013-0018-9"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-013-0018-9'
This table displays all metadata directly associated to this object as RDF triples.
290 TRIPLES
21 PREDICATES
73 URIs
40 LITERALS
28 BLANK NODES